类风湿性关节炎对阿尔茨海默病的影响:一个双样本双向门德尔随机化研究
Songxin Zhong1,2, Changqiang Feng1,2, Shizhan Li1,2
1Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Medicine
|December 16, 2025
概括
类风湿性关节炎 (RA) 因果性地增加了阿尔茨海默病 (AD) 的风险,但AD不会影响RA风险. 在RA患者的早期认知查可能有助于预防AD的进展.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
背景情况:
- 类风湿性关节炎 (RA) 和阿尔茨海默病 (AD) 风险之间的关系受到争论,观察性研究仅限于混和反向因果关系.
- 门德尔随机化 (MR) 提供了一种强大的方法来研究使用遗传变异的因果关系.
研究的目的:
- 通过双向双样本的门德尔随机化 (MR) 研究,调查类风湿性关节炎 (RA) 和阿尔茨海默病 (AD) 风险之间的潜在因果关系.
- 为了确定RA是否会增加AD风险,或者AD是否会影响RA发展.
主要方法:
- 利用来自大型全基因组关联研究数据库和RA和AD的FinnGen项目中的遗传数据.
- 采用逆方差加权 (IVW) 作为主要的MR方法,并补充了MR-Egger,加权中位数和加权模式分析.
- 进行了灵敏度分析,包括科克兰Q测试,MR-Egger拦截,MR-PRESSO,留出一项分析和漏斗图表,以评估异质性,性和结果的稳定性.
主要成果:
- 基因预测的RA对患AD的风险产生了显著的积极因果作用 (IVW OR=1.062,P=0.004).
- 反向MR分析显示,AD对RA风险没有显著的因果关系 (所有P>0.05).
- 没有检测到显著的异质性或质性,敏感性分析证实了研究结果的可靠性.
结论:
- 这项双向MR研究提供了强有力的因果关系证据,表明类风湿性关节炎增加了阿尔茨海默病的风险.
- 研究结果表明,RA患者的早期认知功能查可能是防止未来AD进展的有价值策略.
更多相关视频
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
778
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.7K
相关概念视频
Genome-wide Association Studies-GWAS
15.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.2K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
